Charles River Laboratories (CRL) Announces Avian Vaccine Divestiture
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Charles River Labs (CRL) PT Raised to $250 at Jefferies
November 3, 2022 8:14 AM EDTJefferies analyst David Windley raised the price target on Charles River Labs (NYSE: CRL) to $250.00 (from $240.00) while maintaining a Buy rating.
The analyst commented, "In broad strokes, the composition of CRL's strong report was as we expected in our upgrade. Consolidated... More
Charles River Laboratories (CRL) Tops Q3 EPS by 9c, Offers Guidance
November 2, 2022 7:06 AM EDTCharles River Laboratories (NYSE: CRL) reported Q3 EPS of $2.63, $0.09 better than the analyst estimate of $2.54. Revenue for the quarter came in at $989.2 million versus the consensus estimate of $974.65 million.
GUIDANCE:
Charles River Laboratories sees FY2022 EPS of $10.80-$10.95, versus the consensus of... More
